US Food and Drug Administration staff continue to meet user fee goal dates for product reviews, but stakeholders worry that delays are imminent given the substantial agency resources now devoted to the coronavirus pandemic.
Multiple sponsors and others agree with the FDA's statement that application decision goals remain on track